1. How many patients have been treated with the following drugs in the past 4 months:

* Atogepant (Aquipta) – any disease - 0
* Erenumab (Aimovig) - any disease - 230
* Eptinezumab (Vyepti) – any disease - 0
* Fremanezumab (Ajovy) - any disease - 991
* Galcanezumab (Emgality) - any disease - 97
* Rimegepant (Vydura) – any disease - 2
* Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY - 682

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

|  |  |  |
| --- | --- | --- |
| **Drugs** | **Chronic Migraine (15+ headache days per month)** | **Episodic Migraine (4-15 headache days per month)** |
| Atogepant | 0 | 0 |
| Erenumab | 273 | 21 |
| Eptinezumab | 0 | 0 |
| Fremanezumab | 1286 | 80 |
| Galcanezumab | 112 | 13 |
| Rimegepant | 0 | 0 |
| Botulinum Toxin | 682 | 682 |

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)? YES